Status:
NOT_YET_RECRUITING
Safety and Feasibility of Immuno-OCT
Lead Sponsor:
University Medical Center Groningen
Conditions:
Colon Carcinoma
Barrett Esophagus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To improve detection of premalignant lesions in the gastrointestinal tract (the rectum and the esophagus) there is a need for better endoscopic visualization and the ability for targeted biopsies. The...
Eligibility Criteria
Inclusion
- Indication for a therapeutic endoscopy procedure (EMR or ESD);
- Age ≥ 18;
- Written informed consent.
Exclusion
- Patients younger than 18 years old;
- Submucosal and invasive esophageal adenocarcinoma (EAC) or colorectal carcinoma (CRC);
- Radiation therapy for esophageal or colorectal cancer;
- History of infusion reactions to Bevacizumab or other monoclonal antibodies;
- Chemotherapy, immunotherapy or surgery 28 days before administration of the tracer;
- Non-adjustable hypertension;
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent;
- Pregnancy or breastfeeding; a negative pregnancy test must be available for women of childbearing potential.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06008522
Start Date
April 1 2024
End Date
March 1 2025
Last Update
March 20 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.